Nashik-based custom-synthesis manufacturer of speciality chemicals, APIs, drug intermediates and personal-care ingredients
Price
Market Cap
Sector
Commodities
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves | 5 | 2 | -7 | -6 | -6 | -16 | -19 | -17 |
| Borrowings | 20 | 23 | 24 | 27 | 26 | 36 | 31 | 32 |
| Other Liabilities | 14 | 9 | 12 | 13 | 9 | 9 | 14 | 11 |
| Total Liabilities | 51 | 47 | 42 | 46 | 42 | 43 | 39 | 39 |
| AssetsFixed Assets | 25 | 26 | 24 | 23 | 22 | 22 | 22 | 21 |
| CWIP | 3 | 0 | 1 | 1 | 2 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 23 | 21 | 16 | 22 | 18 | 20 | 17 | 17 |
| Total Assets | 51 | 47 | 42 | 46 | 42 | 43 | 39 | 39 |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | -1 | 4 | -0 | 1 | -0 | 2 | -7 | 6 |
| Cash from Investing | -8 | -2 | 0 | -1 | -1 | -1 | -1 | -1 |
| Cash from Financing | 9 | -2 | 1 | -1 | 1 | -2 | 9 | -6 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -10 | 2 | -0 | 0 | -1 | 2 | -8 | 6 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
VSCL · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.